FR2473525A1 - Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments - Google Patents
Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments Download PDFInfo
- Publication number
- FR2473525A1 FR2473525A1 FR8000566A FR8000566A FR2473525A1 FR 2473525 A1 FR2473525 A1 FR 2473525A1 FR 8000566 A FR8000566 A FR 8000566A FR 8000566 A FR8000566 A FR 8000566A FR 2473525 A1 FR2473525 A1 FR 2473525A1
- Authority
- FR
- France
- Prior art keywords
- radical
- formula
- product
- products
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims abstract description 30
- 229960003276 erythromycin Drugs 0.000 title claims description 14
- 150000002923 oximes Chemical class 0.000 title claims description 12
- 239000003814 drug Substances 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 13
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims abstract description 7
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims abstract description 6
- 125000005110 aryl thio group Chemical group 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- -1 1,2-epoxyethyl group Chemical group 0.000 claims description 57
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000007524 organic acids Chemical class 0.000 claims description 8
- 235000005985 organic acids Nutrition 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 150000007522 mineralic acids Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 6
- 229940126601 medicinal product Drugs 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 5
- 125000005108 alkenylthio group Chemical group 0.000 claims description 5
- 125000005109 alkynylthio group Chemical group 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 229910052788 barium Inorganic materials 0.000 claims description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical compound O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- GWBWGPRZOYDADH-UHFFFAOYSA-N [C].[Na] Chemical compound [C].[Na] GWBWGPRZOYDADH-UHFFFAOYSA-N 0.000 claims 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 3
- 125000002947 alkylene group Chemical group 0.000 abstract description 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000047 product Substances 0.000 description 89
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- KYTWXIARANQMCA-PGYIPVOXSA-N (3r,4s,5s,6r,7r,9r,10z,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradec Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N\O)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-PGYIPVOXSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- CYLJJGWXJNNBDU-UHFFFAOYSA-N 2-[2,3-bis(2-aminoethyl)phenyl]ethanamine Chemical compound NCCC1=CC=CC(CCN)=C1CCN CYLJJGWXJNNBDU-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 229940050176 methyl chloride Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- MXKLLZKHYHDXPG-UHFFFAOYSA-N 1-(chloromethoxy)-2-ethoxyethane Chemical compound CCOCCOCCl MXKLLZKHYHDXPG-UHFFFAOYSA-N 0.000 description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930006677 Erythromycin A Natural products 0.000 description 2
- MWFRKHPRXPSWNT-UHFFFAOYSA-N Erythromycin-C Natural products CC1C(OC2C(C(CC(C)O2)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(O)(C)C(CC)OC(=O)C(C)C1OC1CC(C)(O)C(O)C(C)O1 MWFRKHPRXPSWNT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 2
- TYQXKHPOXXXCTP-CSLYCKPJSA-N erythromycin A 2'-propanoate Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 TYQXKHPOXXXCTP-CSLYCKPJSA-N 0.000 description 2
- IDRYSCOQVVUBIJ-PPGFLMPOSA-N erythromycin B Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 IDRYSCOQVVUBIJ-PPGFLMPOSA-N 0.000 description 2
- 229950001028 erythromycin propionate Drugs 0.000 description 2
- 125000005290 ethynyloxy group Chemical group C(#C)O* 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NTHKNMPHBNQTJM-UHFFFAOYSA-N 1-chloro-n,n-dimethylethanamine;hydrochloride Chemical compound Cl.CC(Cl)N(C)C NTHKNMPHBNQTJM-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- IDRYSCOQVVUBIJ-UHFFFAOYSA-N Erythromycin-B Natural products CC1C(OC2C(C(CC(C)O2)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(C)C(CC)OC(=O)C(C)C1OC1CC(C)(OC)C(O)C(C)O1 IDRYSCOQVVUBIJ-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- UHLVPIUEYJGQHG-UHFFFAOYSA-N N-chloro-N-methylmethanamine hydrochloride Chemical compound Cl.CN(C)Cl UHLVPIUEYJGQHG-UHFFFAOYSA-N 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- RZKYEQDPDZUERB-UHFFFAOYSA-N Pindone Chemical group C1=CC=C2C(=O)C(C(=O)C(C)(C)C)C(=O)C2=C1 RZKYEQDPDZUERB-UHFFFAOYSA-N 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 206010056430 Staphylococcal sepsis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- MMFVFNVXXDFELX-UHFFFAOYSA-N chloroform;n,n-diethylethanamine Chemical compound ClC(Cl)Cl.CCN(CC)CC MMFVFNVXXDFELX-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- SYHPANJAVIEQQL-UHFFFAOYSA-N dicarboxy carbonate Chemical compound OC(=O)OC(=O)OC(O)=O SYHPANJAVIEQQL-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- AQFWNELGMODZGC-UHFFFAOYSA-N o-ethylhydroxylamine Chemical compound CCON AQFWNELGMODZGC-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000000177 propargylthio group Chemical group [H]C#CC([H])([H])S* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (28)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8000566A FR2473525A1 (fr) | 1980-01-11 | 1980-01-11 | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| IL61808A IL61808A (en) | 1980-01-11 | 1980-12-26 | Oxime derivatives of erythromycin a,their preparation and pharmaceutical compositions containing them |
| ZA00808108A ZA808108B (en) | 1980-01-11 | 1980-12-30 | Oximes derived from erthyromycin a,their preparation ,their use as medicaments and the pharmaceutical compositions containing them |
| US06/223,368 US4349545A (en) | 1980-01-11 | 1981-01-08 | Novel erythromycin a derivatives |
| FI810042A FI69473C (fi) | 1980-01-11 | 1981-01-08 | Foerfarande foer framstaellning av terapeutiskt anvaendbara deivat av erytromycin |
| AT81400026T ATE9161T1 (de) | 1980-01-11 | 1981-01-09 | Oxim-derivate von erythromycin a, ihre herstellung, ihre verwendung als pharmazeutika und sie enthaltende pharmazeutische zusammensetzungen. |
| IE46/81A IE50680B1 (en) | 1980-01-11 | 1981-01-09 | New oxime derivatives of erythromycin a,processes for their preparation,and pharmaceutical compositions containing them |
| DK007881A DK157878C (da) | 1980-01-11 | 1981-01-09 | Fremgangsmaade til analogifremstilling af erythromycinderivater |
| PT72331A PT72331B (fr) | 1980-01-11 | 1981-01-09 | Procede de preparation de nouvelles oximes derives de l'erythromycine a |
| JP126481A JPS56100799A (en) | 1980-01-11 | 1981-01-09 | Novel oxime derivatives of erythromycin* their manufacture*their use as drug and pharmaceutical composition containing them |
| CA000368249A CA1162535A (fr) | 1980-01-11 | 1981-01-09 | Procede de preparation de nouvelles oximes derives de l'erythromycine a |
| AU66131/81A AU537247B2 (en) | 1980-01-11 | 1981-01-09 | Oxime derivatives of erythromycin a |
| OA57295A OA06719A (fr) | 1980-01-11 | 1981-01-09 | Nouvelles oximes dérivées de l'érythromycine A, leur préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| HU8155A HU187760B (en) | 1980-01-11 | 1981-01-09 | Process for preparing new oxime derivatives of erythromycin a |
| DE8181400026T DE3165720D1 (en) | 1980-01-11 | 1981-01-09 | Oximes derived from erythromycin a, their preparation, their application in pharmaceuticals and pharmaceutical compositions containing them |
| ES498395A ES8200702A1 (es) | 1980-01-11 | 1981-01-09 | Procedimiento para preparar derivados de la eritromicina |
| EP81400026A EP0033255B1 (fr) | 1980-01-11 | 1981-01-09 | Nouvelles oximes dérivées de l'érythromycine A, leur préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant |
| GR63831A GR73103B (en, 2012) | 1980-01-11 | 1981-01-09 | |
| CY1319A CY1319A (en) | 1980-01-11 | 1981-01-09 | Oximes derived from erythromycin a,their preparation,their application in pharmaceuticals and pharmaceutical compositions containing them |
| KR1019810000051A KR850000964B1 (ko) | 1980-01-11 | 1981-01-10 | 에리트로마이신a의 옥심 유도체류의 제조방법 |
| KR1019850002197A KR850001179B1 (ko) | 1980-01-11 | 1985-03-30 | 에리트로마이신 a의 옥심 유도체류의 제조방법 |
| GT198500080A GT198500080A (es) | 1980-01-11 | 1985-09-12 | Procedimiento para preparar derivados de la eritromicina. |
| KE356685A KE3566A (en) | 1980-01-11 | 1985-10-01 | Nouvelles oximes derivatives de l'erythromycine a,leur preparation,leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| MY984/85A MY8500984A (en) | 1980-01-11 | 1985-12-30 | New oxime derivatives of erythromycin a, their preparation,their application as medicaments and the pharmaceutical compositions containing them |
| HK5/86A HK586A (en) | 1980-01-11 | 1986-01-02 | Oximes derived from erythromycin a, their preparation, their application in pharmaceuticals and pharmaceutical compositions containing them |
| LU88283C LU88283I2 (fr) | 1980-01-11 | 1993-06-03 | Rulid |
| NL930097C NL930097I2 (nl) | 1980-01-11 | 1993-06-25 | Nieuwe oximen van erytromycine A, hun bereiding, hun toepassing als geneesmiddelen en farmaceutischepreparaten, die hen bevatten. |
| BG098506A BG61369B2 (bg) | 1980-01-11 | 1994-02-22 | Нови оксими производни на еритромицин а, получаването им,приложението им като лекарствени средства и съдържащите ги фармацевтични състави |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8000566A FR2473525A1 (fr) | 1980-01-11 | 1980-01-11 | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2473525A1 true FR2473525A1 (fr) | 1981-07-17 |
| FR2473525B1 FR2473525B1 (en, 2012) | 1983-04-15 |
Family
ID=9237443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8000566A Granted FR2473525A1 (fr) | 1980-01-11 | 1980-01-11 | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4349545A (en, 2012) |
| EP (1) | EP0033255B1 (en, 2012) |
| JP (1) | JPS56100799A (en, 2012) |
| KR (1) | KR850000964B1 (en, 2012) |
| AU (1) | AU537247B2 (en, 2012) |
| BG (1) | BG61369B2 (en, 2012) |
| CA (1) | CA1162535A (en, 2012) |
| CY (1) | CY1319A (en, 2012) |
| DE (1) | DE3165720D1 (en, 2012) |
| DK (1) | DK157878C (en, 2012) |
| ES (1) | ES8200702A1 (en, 2012) |
| FI (1) | FI69473C (en, 2012) |
| FR (1) | FR2473525A1 (en, 2012) |
| GR (1) | GR73103B (en, 2012) |
| GT (1) | GT198500080A (en, 2012) |
| HK (1) | HK586A (en, 2012) |
| HU (1) | HU187760B (en, 2012) |
| IE (1) | IE50680B1 (en, 2012) |
| IL (1) | IL61808A (en, 2012) |
| LU (1) | LU88283I2 (en, 2012) |
| MY (1) | MY8500984A (en, 2012) |
| NL (1) | NL930097I2 (en, 2012) |
| OA (1) | OA06719A (en, 2012) |
| PT (1) | PT72331B (en, 2012) |
| ZA (1) | ZA808108B (en, 2012) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2222333C1 (ru) * | 2003-03-06 | 2004-01-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция с антибактериальной активностью и способ ее получения |
| US7342000B2 (en) | 2002-12-12 | 2008-03-11 | Glaxosmithkline Istrazivacki Center Zagreb | Semisynthetic macrolide antibiotics of the azalide series |
| US7365056B2 (en) | 2002-11-11 | 2008-04-29 | Glaxosmithkline Istrazivacki Centar Zagreb D.O | Substituted 9a-N-(N′-(sulfonyl)phenylcarbamoyl)derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithomycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9-a-aza-9a-homoerithronolide A |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534588B2 (fr) * | 1982-10-15 | 1985-09-20 | Roussel Uclaf | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| US4526889A (en) * | 1982-11-15 | 1985-07-02 | Pfizer Inc. | Epimeric azahomoerythromycin A derivative, intermediates and method of use |
| DK149776C (da) * | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
| JPS60214796A (ja) * | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | ６−０−メチルエリスロマイシン類の製法 |
| JPS61103890A (ja) * | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | ６−０−メチルエリスロマイシンａ誘導体 |
| US4847242A (en) | 1985-03-12 | 1989-07-11 | Beecham Group P.L.C. | 11-ether derivatives of erythromycins |
| JPS61229895A (ja) * | 1985-04-03 | 1986-10-14 | Nippon Zeon Co Ltd | 保護化デス−ｎ−メチルエリスロマイシン誘導体 |
| US4740502A (en) * | 1986-06-20 | 1988-04-26 | Abbott Laboratories | Semisynthetic erythromycin antibiotics |
| DE3782994T2 (de) | 1986-09-18 | 1993-04-08 | Taisho Pharma Co Ltd | Erythromycin-a-derivate und verfahren zu ihrer herstellung. |
| JP2751385B2 (ja) * | 1988-05-19 | 1998-05-18 | 大正製薬株式会社 | エリスロマイシンａオキシム及びその塩の製造方法 |
| US5075289A (en) * | 1988-06-07 | 1991-12-24 | Abbott Laboratories | 9-r-azacyclic erythromycin antibiotics |
| US5302705A (en) * | 1989-10-07 | 1994-04-12 | Taisho Pharmaceutical Co., Ltd. | 6-O-methylerythromycin a oxime derivatives |
| US5912331A (en) * | 1991-03-15 | 1999-06-15 | Merck & Co., Inc. | Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A |
| DE69227713D1 (de) | 1991-03-15 | 1999-01-14 | Merck & Co Inc | 9-Deoxo-9(Z)-hydroxyiminoerythromycin A und O-Derivate hiervon |
| US5985844A (en) * | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
| US5189159A (en) * | 1992-04-02 | 1993-02-23 | Merck & Co., Inc. | 8a-AZA-8a-homoerythromycin cyclic iminoethers |
| ES2036472B1 (es) * | 1991-10-01 | 1994-03-01 | Prodesfarma Sa | Procedimiento de obtencion de eritromicina 9-(0-((2-metoxietoxi)metil)oxima) (roxitromicina). |
| US5210235A (en) * | 1992-08-26 | 1993-05-11 | Merck & Co., Inc. | Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics |
| US5332807A (en) * | 1993-04-14 | 1994-07-26 | Merck & Co., Inc. | Process of producing 8A- and 9A-azalide antibiotics |
| US5795871A (en) * | 1994-04-26 | 1998-08-18 | Nobuhiro Narita | Pharmaceutical composition for treatment of non-small cell lung cancer |
| IT1276901B1 (it) * | 1994-12-13 | 1997-11-03 | Zambon Spa | Derivati dell'eritromicina a 9-0-ossina dotati di attivita' antibiotica |
| US5872229A (en) | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
| FR2760017B1 (fr) * | 1997-02-27 | 1999-04-30 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erytromycine, leur procede de preparation et leur application comme medicaments |
| US5929219A (en) | 1997-09-10 | 1999-07-27 | Abbott Laboratories | 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same |
| PT102202B (pt) | 1998-09-10 | 2001-04-30 | Hovione Sociedade Quimica S A | Processo para a purificacao de roxitromicina |
| IN190782B (en, 2012) * | 1998-09-30 | 2003-08-23 | Max India Ltd | |
| DE69813244T2 (de) * | 1998-11-24 | 2004-03-04 | Jubilant Organosys Ltd. | Verfahren zur Herstellung von Roxithromycin und Derivate davon |
| CZ20021999A3 (cs) | 1999-12-16 | 2003-02-12 | Teva Pharmaceutical Industries Ltd. | Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV |
| IL150698A0 (en) * | 2000-01-11 | 2003-02-12 | Teva Pharma | Processes for preparing clarithromycin polymorphs |
| WO2001064224A1 (en) | 2000-02-29 | 2001-09-07 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
| EP1435359A1 (en) * | 2002-12-31 | 2004-07-07 | Alembic Limited | A process for the purification of roxithromycin |
| KR20090042971A (ko) | 2006-08-24 | 2009-05-04 | 욱크하르트 리서치 센터 | 항미생물 활성을 갖는 신규한 마크로라이드 및 케토라이드 |
| US20090005326A1 (en) * | 2007-06-26 | 2009-01-01 | Idexx Laboratories, Inc. | Single dose roxithromycin |
| CA2820451C (en) | 2010-12-09 | 2017-12-12 | Wockhardt Limited | Ketolide compounds |
| EP2681222B1 (en) | 2011-03-01 | 2018-02-28 | Wockhardt Limited | Process for preparation of ketolide intermediates |
| CA2830861C (en) | 2011-03-22 | 2017-01-24 | Wockhardt Limited | Process for preparation of ketolide compounds |
| CN102219816A (zh) * | 2011-05-12 | 2011-10-19 | 浙江国邦药业有限公司 | 一种罗红霉素的纯化方法 |
| PL222631B1 (pl) | 2012-11-14 | 2016-08-31 | Gdański Univ Medyczny | Kompozycja farmaceutyczna zawierająca roksytromycynę, sposób jej wytwarzania oraz zastosowanie medyczne tej kompozycji i produkt leczniczy zawierający kompozycję |
| CN104163840A (zh) * | 2013-08-30 | 2014-11-26 | 郑州后羿制药有限公司 | 一种罗红霉素的精制方法 |
| FR3049861A1 (fr) | 2016-04-07 | 2017-10-13 | Univ Claude Bernard Lyon | Nouvelles compositions antivirales pour le traitement de la grippe |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2201874A1 (en, 2012) * | 1972-10-10 | 1974-05-03 | Abbott Lab | |
| DE2515076A1 (de) * | 1975-04-07 | 1976-10-28 | Thomae Gmbh Dr K | Neue erythromycinderivate, deren salze und verfahren zu ihrer herstellung |
| DE2515077A1 (de) * | 1975-04-07 | 1976-10-28 | Thomae Gmbh Dr K | Neue 9-alkylidenamino-erythromycine, ihre salze und verfahren zu ihrer herstellung |
| SU664568A3 (ru) * | 1967-08-03 | 1979-05-25 | Плива Фабрика Фармацевтических И Химических Продуктов (Фирма) | Способ получени ацилпроизводных эритромициноксима |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES434842A1 (es) * | 1975-02-19 | 1976-12-01 | Andreu Sa Dr | Procedimiento para la preparacion de esteres de la oxima deeritromicina. |
| DK139522C (da) * | 1975-04-07 | 1979-08-20 | Thomae Gmbh Dr K | Analogifremgangsmaade til fremstilling af 9-iminoalkylamino-erythromyciner eller syreadditionssalte deraf |
| DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
-
1980
- 1980-01-11 FR FR8000566A patent/FR2473525A1/fr active Granted
- 1980-12-26 IL IL61808A patent/IL61808A/xx not_active IP Right Cessation
- 1980-12-30 ZA ZA00808108A patent/ZA808108B/xx unknown
-
1981
- 1981-01-08 US US06/223,368 patent/US4349545A/en not_active Expired - Lifetime
- 1981-01-08 FI FI810042A patent/FI69473C/fi not_active IP Right Cessation
- 1981-01-09 DE DE8181400026T patent/DE3165720D1/de not_active Expired
- 1981-01-09 DK DK007881A patent/DK157878C/da active
- 1981-01-09 HU HU8155A patent/HU187760B/hu unknown
- 1981-01-09 CA CA000368249A patent/CA1162535A/fr not_active Expired
- 1981-01-09 JP JP126481A patent/JPS56100799A/ja active Granted
- 1981-01-09 EP EP81400026A patent/EP0033255B1/fr not_active Expired
- 1981-01-09 CY CY1319A patent/CY1319A/xx unknown
- 1981-01-09 ES ES498395A patent/ES8200702A1/es not_active Expired
- 1981-01-09 OA OA57295A patent/OA06719A/xx unknown
- 1981-01-09 GR GR63831A patent/GR73103B/el unknown
- 1981-01-09 PT PT72331A patent/PT72331B/pt unknown
- 1981-01-09 AU AU66131/81A patent/AU537247B2/en not_active Expired
- 1981-01-09 IE IE46/81A patent/IE50680B1/en not_active IP Right Cessation
- 1981-01-10 KR KR1019810000051A patent/KR850000964B1/ko not_active Expired
-
1985
- 1985-09-12 GT GT198500080A patent/GT198500080A/es unknown
- 1985-12-30 MY MY984/85A patent/MY8500984A/xx unknown
-
1986
- 1986-01-02 HK HK5/86A patent/HK586A/xx not_active IP Right Cessation
-
1993
- 1993-06-03 LU LU88283C patent/LU88283I2/fr unknown
- 1993-06-25 NL NL930097C patent/NL930097I2/nl unknown
-
1994
- 1994-02-22 BG BG098506A patent/BG61369B2/bg unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU664568A3 (ru) * | 1967-08-03 | 1979-05-25 | Плива Фабрика Фармацевтических И Химических Продуктов (Фирма) | Способ получени ацилпроизводных эритромициноксима |
| FR2201874A1 (en, 2012) * | 1972-10-10 | 1974-05-03 | Abbott Lab | |
| DE2515076A1 (de) * | 1975-04-07 | 1976-10-28 | Thomae Gmbh Dr K | Neue erythromycinderivate, deren salze und verfahren zu ihrer herstellung |
| DE2515077A1 (de) * | 1975-04-07 | 1976-10-28 | Thomae Gmbh Dr K | Neue 9-alkylidenamino-erythromycine, ihre salze und verfahren zu ihrer herstellung |
Non-Patent Citations (2)
| Title |
|---|
| CA1977 * |
| CA1979 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365056B2 (en) | 2002-11-11 | 2008-04-29 | Glaxosmithkline Istrazivacki Centar Zagreb D.O | Substituted 9a-N-(N′-(sulfonyl)phenylcarbamoyl)derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithomycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9-a-aza-9a-homoerithronolide A |
| US7342000B2 (en) | 2002-12-12 | 2008-03-11 | Glaxosmithkline Istrazivacki Center Zagreb | Semisynthetic macrolide antibiotics of the azalide series |
| RU2222333C1 (ru) * | 2003-03-06 | 2004-01-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция с антибактериальной активностью и способ ее получения |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2473525A1 (fr) | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| EP0799833B1 (fr) | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments | |
| CA2055912C (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation, les nouveaux intermediaires obtenus et leur application comme medicaments | |
| EP0885234B1 (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| EP0606024B1 (fr) | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments | |
| EP1016669B1 (fr) | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments | |
| FR2727969A1 (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| EP0974598B1 (fr) | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments | |
| CA2258152C (fr) | Nouveaux derives aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments | |
| CA2282666C (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| CA1132537A (fr) | Procede de preparation de nouvelles oximes derivees de l'acide 3-thiadiazolyl thiomethyl 7-aminothiazolyl acetamido cephalosporanique | |
| CA2273985C (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| FR2754821A1 (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| US4686207A (en) | Erythromycin A 11,12-carbonates and method of use | |
| JPH0216758B2 (en, 2012) | ||
| FR2638458A1 (fr) | Nouveaux derives de la tylosine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FR2534588A2 (fr) | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| FR2757518A1 (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| CA2247175C (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| FR2669337A1 (fr) | Nouveaux derives descladinosyles de l'erythromycine, leur procede de preparation et leur application comme medicaments. | |
| FR2614894A1 (fr) | Nouvelles oximes derivees de la tylosine, leur procede de preparation et les compositions pharmaceutiques les contenant | |
| FR2792637A1 (fr) | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
| EP1098901A1 (fr) | Nouveaux derives de la 6-deoxy erythromycine, leur procede de preparation et leur application comme medicaments | |
| FR2626576A1 (fr) | Nouveaux derives de la carbomycine b, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FR2773369A1 (fr) | Nouveaux amides aromatiques, leur procede de preparation et leur application comme medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CA | Change of address | ||
| CD | Change of name or company name | ||
| TP | Transmission of property |